Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rezolute, Inc. (NASDAQ:RZLT) detailed its advanced antibody therapy for hyperinsulinism (HI), a rare disease, highlighting its universal application for both congenital and tumor forms. A critical catalyst is the upcoming Phase III sunRIZE study data for congenital HI in December 2025. The company also announced FDA alignment for a streamlined Phase III upLIFT study for tumor HI, significantly reducing patient enrollment and accelerating development timelines, underpinned by Breakthrough Therapy Designations for both indications. With BLA filing anticipated mid-2026 and PDUFA in early 2027, Rezolute projects a substantial commercial opportunity in the ultra-rare disease market, driven by high unmet need and strong pricing potential, with plans for independent U.S. commercialization.

Analysis

Rezolute, Inc. (RZLT) is positioned for significant clinical and regulatory milestones with its universal antibody therapy for hyperinsulinism (HI). The company's most immediate catalyst is the Phase III sunRIZE study data readout for congenital HI (CHI), expected in December 2025, which aims to show a 35% efficacy difference versus placebo. A recent and significant development is the FDA's alignment on a streamlined Phase III upLIFT study for tumor-induced HI (TIH), reducing the trial from a 48-patient placebo-controlled study to a 16-patient open-label design. This modification, supported by strong real-world evidence from an expanded access program and Breakthrough Therapy Designations for both indications, substantially de-risks and accelerates the TIH program. Management has outlined a clear regulatory path, targeting a BLA submission in mid-2026 and a potential PDUFA date in early 2027. The commercial opportunity is framed as highly attractive, targeting an estimated 3,500 CHI patients in the U.S. and a TIH market potentially twice as large, with plans for independent U.S. commercialization and robust pricing power derived from the ultra-rare disease setting and weight-based dosing for the adult tumor population.

Key Decisions for Investors

• Investors should focus on the pivotal Phase III sunRIZE data in December 2025 as the primary near-term catalyst and key valuation inflection point.
• The recent FDA alignment on a streamlined Phase III upLIFT study for tumor HI significantly de-risks the asset and accelerates the timeline for a second major indication, which should be factored into valuation models as a fast-follower program.
• Consider the company's stated plan to commercialize independently in the U.S., which offers higher potential returns but also introduces execution risk; monitor key hires and pre-commercialization activities.
• Evaluate the long-term potential of the therapy as a universal treatment for all forms of hyperinsulinism, a position that could command a durable market share given the high unmet need and lack of direct late-stage competitors.